DFX Intelligence
Data Factory
Reading the graph
Reading the graph
Venture Capital
Ascenta Capital was born to help innovative companies as they grow from their scientific foundations to advance the clinical development of meaningful medicines for patients.
Data as of (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built and rebuilt at most every 15 minutes.
This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.
| Fund | Vintage | Lifecycle | Form D sold | GAV | LPs |
|---|---|---|---|---|---|
| Ascenta Capital Project Turing Spv, L.P. | 2024 | Early deployment | n/a | $820,000 | 0 |
| Ascenta Capital Project Argos Spv, L.P. | 2024 | Early deployment | n/a | $1.2M | 0 |
| Ascenta Capital Fund I, L.P. | 2023 | Active deployment | $228M | $118M | 0 |
| Ascenta Capital Spv I, L.P. | 2023 | Active deployment | $15.0M | $0 | 0 |
| Company | State | Stage | Round size | Partner | Attribution | Observed |
|---|---|---|---|---|---|---|
| Alpha-9 Oncology | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Angitia | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Cardurion Pharmaceuticals, Inc. | Ma | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Iambic Therapeutics, Inc. | CA | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Latigo | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| OrsoBio, Inc. | CA | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Triana Biomedicines, Inc. | Ma | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Triveni Bio | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Tubulis | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Polyvore | n/a | n/a | n/a | n/a | Unknown | Sep 14, 2026 |
| Nasdaq: ODTX | n/a | n/a | n/a | n/a | Unknown | Sep 14, 2026 |
| Triveni Bio | n/a | Series c | $65.0M | n/a | Unknown | Jun 17, 2026 |
| Investor | Co-investor | Shared deals | Shared companies | Last observed | Strength |
|---|---|---|---|---|---|
| Ascenta Capital | Delos Advisors, Inc. | 1 | 1 | Sep 16, 2026 | One time |
| Ascenta Capital | Lightspeed Venture Partners | 1 | 1 | Sep 17, 2026 | One time |
| DAG Ventures | Ascenta Capital | 1 | 1 | Sep 14, 2026 | One time |
| Khosla Ventures, LLC | Ascenta Capital | 1 | 1 | Sep 18, 2026 | One time |
| Long Journey Ventures | Ascenta Capital | 1 | 1 | Sep 18, 2026 | One time |
| Ascenta Capital | Frist Cressey Ventures | 1 | 1 | Sep 18, 2026 | One time |
| Ascenta Capital | General Catalyst | 1 | 1 | Sep 18, 2026 | One time |
| Ascenta Capital | Andreessen Horowitz | 1 | 1 | Sep 18, 2026 | One time |
| Ascenta Capital | YLV Management LLC | 1 | 1 | Sep 14, 2026 | One time |
| Nexus | Ascenta Capital | 1 | 1 | Sep 16, 2026 | One time |
| Matrix | Ascenta Capital | 1 | 1 | Sep 16, 2026 | One time |
Also named here, with no published line of their own (reach them through the firm): Lorence H. Kim (Managing Member), Evan Lockwood Rachlin (Managing Member).
Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan